Concord Biotech Limited (BOM:543960)
1,046.80
-20.60 (-1.93%)
At close: Apr 21, 2026
Concord Biotech Revenue
Concord Biotech had revenue of 2.78B INR in the quarter ending December 31, 2025, with 13.74% growth. This brings the company's revenue in the last twelve months to 11.59B, up 6.38% year-over-year. In the fiscal year ending March 31, 2025, Concord Biotech had annual revenue of 12.00B with 18.01% growth.
Revenue (ttm)
11.59B
Revenue Growth
+6.38%
P/S Ratio
9.42
Revenue / Employee
7.38M
Employees
1,571
Market Cap
109.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | 6.17B | 1.05B | 20.42% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 79.18B |
| Granules India | 50.92B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| AstraZeneca Pharma India | 21.77B |
| Caplin Point Laboratories | 20.92B |
| FDC Limited | 20.78B |
| Sanofi India | 18.37B |
| Viyash Scientific | 18.17B |